Company Overview of Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company’s lead product candidate is entinostat, an epigenetic therapy for treatment-resistant cancers, such as breast cancer and lung cancer, as well as other indications comprising solid tumors and hematological malignancies. Its Entinostat is an oral histone deacetylase inhibitor that targets cancer cell growth and resistance pathways that limit the effectiveness and durability of cancer therapies. The company has a collaborative research and development agreement with the National Cancer Institute; and Genentech. Syndax Pharmaceuticals, In...
400 Totten Pond Road
Waltham, MA 02451
Founded in 2005
Key Executives for Syndax Pharmaceuticals, Inc.
Chief Executive Officer and Director
Total Annual Compensation: $373.4K
President and Chief Operating Officer
Total Annual Compensation: $346.5K
Chief Medical Officer and Senior Vice President
Total Annual Compensation: $140.6K
Compensation as of Fiscal Year 2015.
Syndax Pharmaceuticals, Inc. Key Developments
Syndax Pharmaceuticals, Inc. Announces Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2016
Aug 9 16
Syndax Pharmaceuticals, Inc. announced consolidated unaudited earnings results for the second quarter and six months ended June 30, 2016. For the quarter, the company reported license fee revenue of $305,000 compared to $17,000 a year ago. Loss from operations was $8,634,000 compared with $5,542,000 for the same period a year ago. Net loss attributable to common stockholders was $8,358,000 or $0.47 per basic and diluted share compared with $26,338,000 or $440.52 per basic and diluted share for the same period a year ago. The net loss for the three months ended June 30, 2016, included non-cash stock-based compensation expense of $0.8 million related to the issuance of stock option awards to employees and non-employees.
For the six months, the company reported license fee revenue of $610,000 compared to $17,000 a year ago. Loss from operations was $17,387,000 compared with $9,976,000 for the same period a year ago. Net loss attributable to common stockholders was $21,286,000 or $1.19 per basic and diluted share compared with $38,410,000 or $649.30 per basic and diluted share for the same period a year ago.
Syndax Pharmaceuticals, Inc. Appoints Board of Directors
Jul 27 16
Syndax Pharmaceuticals, Inc. announced the appointment of seven oncology experts to its Scientific Advisory Board. The members of Syndax’s SAB are: Ronald M. Evans, Ph.D. (SAB Chair and Syndax co-founder) is a Professor in the Gene Expression Laboratory at the Salk Institute for Biological Studies, a Howard Hughes Medical Institute Investigator, and holds the March of Dimes Chair in Developmental and Molecular Biology at the Salk Institute. Julie R. Brahmer, M.D., M.Sc. is Director of the Thoracic Oncology Program and Associate Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, as well as Interim Director of the Johns Hopkins Kimmel Cancer Center at Bayview. In addition, she serves as co-Principal Investigator on the Johns Hopkins’ NCI National Clinical Trials Network (NCTN) Program grant and helps direct all oncology cooperative group activities on the Johns Hopkins campuses. Joseph Paul Eder, M.D. is Director of the Early Drug Development Program and Assistant Director of Experimental Therapeutics at Yale Cancer Center. Previously Dr. Eder was the Medical Science Director for AstraZeneca’s Boston site and prior to that he was Clinical Director of the Dana Farber Cancer Institute General Cancer Research Center. Rachel Humphrey, M.D. is currently Chief Medical Officer at CytomX, an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on its Probody platform. Previously, Dr. Humphrey has held positions as Vice President and Head of Immuno-oncology both at Eli Lilly and at AstraZeneca and prior to that was Vice President of Product Development at Bristol-Myers Squibb (BMS). Samir Khleif, M.D. is the Director of the Georgia Cancer Center at Augusta University where he has established a comprehensive Immuno-Oncology Program that connects basic research discovery to clinical trials with highly integrated translational elements. He is a Georgia Research Alliance Distinguished Cancer Scientist and Clinician; professor of Medicine, Biochemistry, Cancer Biology and Graduate Studies; and Director of the Immunoncology and Immunotherapeutic program. Previously, Dr. Khleif served as Chief of the Cancer Vaccine Section at the National Cancer Institute (NCI), and Professor of Medicine at Uniformed Services University of the Health Sciences. Hope S. Rugo, M.D. is Professor of Medicine in the Division of Hematology and Oncology at the University of California San Francisco (UCSF) and Director of Breast Cancer and Clinical Trial Education at the UCSF Helen Diller Family Comprehensive Cancer Center. Jedd D. Wolchok, M.D., Ph.D. is Chief of the Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center (MSK), an associate director of the Ludwig Center for Cancer Immunotherapy at MSK, an associate member of Ludwig Cancer Research, and holds the Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation at MSK. He is director of the CRI/Ludwig Cancer Vaccine Collaborative Trials Network, and is an associate director of the CRI Scientific Advisory Council. He is also the co-director of the Swim Across America laboratory at MSK, one of the foremost immunotherapy and melanoma research groups in the country.
Syndax Pharmaceuticals, Inc. to Report Q2, 2016 Results on Aug 09, 2016
Jul 20 16
Syndax Pharmaceuticals, Inc. announced that they will report Q2, 2016 results Pre-Market on Aug 09, 2016
Similar Private Companies By Industry
Recent Private Companies Transactions